Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon plus multi-signal loaded dendritic cell and conditional cyclophosphamide immunotherapy after resection for HBV-related hepatocellular carcinoma
ChiCTR2000040749Phase 2Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in hepatocellular carcinoma (HCC) and hepatitis B-associated hepatocellular carcinoma (HBV-HCC) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: 1, 2, and 3-year disease-free survival after surgery, 1, 2, and 3-year progression-free survival after surgery and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B-associated hepatocellular carcinoma (HBV-HCC)
Beyond the preview
Go deeper on ChiCTR2000040749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040749.